OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Rudin on Immunotherapy Biomarkers in Lung Cancer

April 25th 2018

Charles M. Rudin, MD, PhD, chief, Thoracic Oncology Service, co-director, Druckenmiller Center for Lung Cancer Research, Sylvia Hassenfeld Chair in Lung Cancer Research, Memorial Sloan Kettering Cancer Center, discusses biomarkers for immunotherapy in lung cancer.

Dr. Atreya on Questions Remaining With Tumor Sidedness in CRC

April 25th 2018

Chloe E. Atreya, MD, PhD, assistant clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses questions regarding sidedness in colorectal cancer.

Dr. Bergsagel on Competing Philosophies of Treatment in Patients With Relapsed Myeloma

April 24th 2018

Leif Bergsagel, MD, consultant and professor of medicine, Division of Hematology/Oncology, Mayo Clinic, discusses competing strategies in treating patients with relapsed multiple myeloma.

Dr. Htut on CAR T-Cell Therapy in Patients With Multiple Myeloma

April 24th 2018

Maung Myo Htut, MD, assistant clinical professor of hematology and hematopoietic cell transplantation, City of Hope, discusses the use of chimeric antigen receptor (CAR) T-cell therapy in patients with multiple myeloma.

Dr. Callahan on Endocrine Therapy in Patients With ER-Positive Breast Cancer

April 24th 2018

Rena D. Callahan, MD, assistant clinical professor of medicine, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses the use of endocrine therapy in patients with estrogen receptor (ER)-positive breast cancer.

Dr. Roussos Torres on the Potential for Immunotherapy in HER2+ Breast Cancer

April 24th 2018

Evanthia Roussos Torres, MD, oncology fellow, Johns Hopkins University School of Medicine, discusses the promise of immunotherapy in the treatment of patients with HER2-positive breast cancer.

Dr. Wei on Immune-Related Adverse Events in GU Cancers

April 24th 2018

Xiao X. Wei, MD, MAS, instructor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses immune-related adverse events (irAE) in genitourinary (GU) cancers.

Dr. Simeone Discusses Unmet Needs in Pancreatic Cancer

April 24th 2018

Diane Simeone, MD, director, Pancreatic Cancer Center, associate director, Translational Research, NYU Langone’s Perlmutter Cancer Center, discusses unmet needs in the treatment of patients with pancreatic cancer.

Dr. Slamon Discusses the Approval Process for Biosimilars

April 24th 2018

Dennis J. Slamon, MD, PhD, director, Clinical/Translational Research, Revlon/University of California, Los Angeles (UCLA) Women's Cancer Research Program, Jonsson Comprehensive Cancer Center, UCLA, discusses the approval process for biosimilars.

Dr. Bosse on the Treatment of Neuroblastoma in Pediatric Patients

April 24th 2018

Kristopher Bosse, MD, attending physician, Division of Oncology, The Children's Hospital of Philadelphia, discusses the treatment of pediatric patients with high-risk neuroblastoma.

Dr. Santin on Impact of Trastuzumab in Uterine Serous Carcinoma

April 24th 2018

Alessandro D. Santin, MD, professor of obstetrics, gynecology, and reproductive sciences at Yale School of Medicine, discusses the impact of trastuzumab (Herceptin) in patients with uterine serous carcinoma.

Dr. Hurvitz on Biosimilars in Breast Cancer

April 23rd 2018

Sara Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses biosimilars in breast cancer.

Dr. Yu on Treatments for EGFR-Mutant Lung Cancer

April 23rd 2018

Helena A. Yu, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses treatments for EGFR-mutant lung cancer.

Dr. Wingo on the Evolution of Surgery in Patients With Ovarian Cancer

April 23rd 2018

Shana Wingo, MD, gynecologic oncologist, Arizona Oncology, discusses surgical options for the treatment of patients with newly-diagnosed ovarian cancer.

Dr. Master on the Relationship Between Diet and Breast Cancer Recurrence

April 22nd 2018

Aashini Master, DO, assistant clinical professor, Division of Hematology/Oncology, University of California, Los Angeles Medical Center, discusses the WINS and WHEL trials in patients with breast cancer.

Dr. DiNome on Surgical Approaches in Patients With Breast Cancer

April 22nd 2018

Maggie DiNome, MD, associate professor of surgery, University of California, Los Angeles Medical Center, discusses the evolution of surgical approaches in patients with breast cancer.

Dr. Duffield on Implications for Immunotherapy in Nasopharyngeal Carcinoma

April 21st 2018

Amy Duffield, MD, PhD, assistant professor of pathology, Johns Hopkins University School of Medicine, member, Johns Hopkins Kimmel Cancer Center, discusses the implications for immunotherapy in nasopharyngeal carcinoma.

CDK 4/6 Inhibitors in Mantle Cell Lymphoma

April 21st 2018

Selina Chen-Kiang, PhD, professor of pathology and immunology, Weill Cornell Medicine, discusses the use of CDK 4/6 inhibitors in mantle cell lymphoma.

Dr. Kopetz Discusses the Treatment of BRAF-Mutant CRC

April 21st 2018

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the treatment of patients with BRAF-mutant colorectal cancer.

Dr. Monk on Combination Therapies in Patients With Ovarian Cancer

April 20th 2018

Bradley J. Monk, MD, professor and director, Division of Gynecologic Oncology, Creighton University School of Medicine, Arizona Oncology, discusses combination approaches in patients with ovarian cancer.